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baseline and at 12 months, and mortality evaluated at 12 to
24 months using adjusted Cox analysis. Factors potentially
involved in PTH status variability between baseline and
12 months were analyzed. A decrease in serum PTH from
normal or high to low values between baseline and
12 months was associated with signiﬁcantly increased
cardiovascular mortality at 12 to 24 months (hazard ratio,
2.03; 95% conﬁdence interval, 1.22–3.36). For patients with
high or normal baseline PTH levels, the main independent
factor at 6 months for a decrease to low PTH levels at
12 months was high dialysate calcium (1.75 mmol/L),
whereas prescription of non–calcium-based phosphate
binders was associated with a lower risk of PTH decrease.
In the high cardiovascular (CV) mortality risk subgroup of
patients who acquired a low PTH status at 12 months, the
main independent factor at 12 months associated with
signiﬁcant 12- to 24-month CV mortality was high dialysate
calcium (odds ratio, 5.44; 95% CI, 2.52–11.75). Thus,
patients with a serum PTH decrease to low values after
1 year of hemodialysis treatment are at high risk of short-
term CV death. High dialysate calcium was an important
contributor to PTH oversuppression, and continued use
was associated with increased CV mortality.
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C ardiovascular (CV) disease is the main cause of deathin patients receiving maintenance dialysis, their risk ofCV death being 10-fold higher than that in the general
population.1 In addition to traditional CV risk factors, other
disorders promote atherosclerosis and arteriosclerosis.2–4
Abnormalities of mineral and bone metabolism—called
“CKD-MBD” for “chronic kidney disease–mineral and bone
disorder”—have been shown to contribute to alterations of
arterial structure and function. Among them, hyperphospha-
temia, hypercalcemia, and secondary hyperparathyroidism
have been associated with CV calciﬁcations, CV events, and
death.5–10 A few studies using heterogeneous methods that
included patients with different dialysis vintages showed an
association between low parathyroid hormone (PTH) levels
and all-cause mortality,8,10–13 and it is well known that at
present, a high proportion of patients receiving dialysis
therapy have relatively low serum PTH levels.13–15 In parallel,
the observation that CV calciﬁcations are more prevalent in
patients undergoing dialysis who have low PTH levels than in
those with normal or moderately elevated levels, in association
with low-turnover bone disease,16,17 supports the hypothesis
that this condition favors mineral deposition in vascular and
other soft tissues instead of bone. Nonetheless, consistent
evidence associating low PTH and CV mortality in patients
undergoing dialysis is still lacking, as is deﬁnitive proof for
the underlying mechanisms. An indicator of the need for addi-
tional data is the low-strength (grade 2C) Kidney Disease:
Improving Global Outcomes (KDIGO) recommendation of
2009 suggesting that PTH levels should be maintained at levels
not less than 2 times the upper limit of healthy individuals.18
We conducted the present study in incident patients
undergoing hemodialysis with the aim to assess the impact ofKidney International (2016) 89, 666–674
E Merle et al.: Cardiovascular death and PTH decrease c l i n i ca l i nves t iga t ionlow PTH status on CV mortality and all-cause mortality and
to identify factors involved in low PTH levels in these
patients.Table 1 | Demographics, baseline characteristics, and
treatment at study entry (month 0) of the 1983 incident
patients undergoing hemodialysis included in the study with
available iPTH at month 0 and month 12a
Characteristics Values
N
observed
Age, yr 67.90 (15.4) 1983
Female sex, n (%) 765 (38.6) 1983
Body mass index, kg/m2 26.05 (5.9) 1490
Diabetes mellitus, n (%) 747 (37.7) 1983
Arterial hypertension, n (%) 1569 (79.1) 1983
Cardiovascular disease, n (%) 1083 (54.6) 1983
Smoking, n (%) 232 (11.7) 1983
History of smoking, n (%) 455 (22.9) 1983
Parathyroidectomy, n (%) 16 (0.8) 1967
Duration of dialysis at study entry, mo 5.81 (3.5) 1983
Hemodialysis, n (%) 1673 (84.4) 1983
Online hemodiaﬁltration, n (%) 310 (15.6) 1983
Kt/V 1.36 (0.3) 1282
Dialysis duration per wk, hr 11.57 (1.8) 1932
History of kidney transplantation 96 (4.8) 1983
Serum total calcium, mmol/L 2.20 (0.2) 1980
Serum albumin, g/L 35.66 (5.0) 1952
Serum phosphate, mmol/L 1.55 (0.5) 1979
Serum iPTH (raw values), pg/ml 220.57 (113.82–388.00) 1983
Low PTH status, n (%) 571 (28.8) 1983
Normal PTH status, n (%) 1208 (60.9) 1983
High PTH status, n (%) 204 (10.3) 1983
Serum 25-OH vitamin D3, ng/ml 26.02 (17.0) 1311
Normalized protein catabolism
rate, g/kg/d
1.15 (0.4) 530
Serum C-reactive protein, mg/L 5.40 (2.90–12.20) 1630RESULTS
As shown in Figure 1, we included 3030 with available intact
PTH (iPTH) patients in October 2010 (month 0). Their
characteristics are given in Supplementary Table S1 online;
2164 patients were still in the cohort in October 2011 (month
12). Among them, 1983 patients had available iPTH values at
month 0 and month 12 and constituted the population of the
study (Figure 1). Of these 1983 patients (Tables 1 and 2),
1200 patients (60.5%) had a normal PTH status at month
0 according to the 2009 KDIGO guidelines, whereas 603
patients (30.4%) had a low PTH status, and only 180 patients
had a high PTH status (9.1%); 571 patients (28.8%) had a low
PTH status at month 12; 365 patients (18.4%) had a low PTH
status at both month 0 and month 12 (low-low group), 282
(14.2%) had a normal or high PTH status at month 0, which
decreased to low PTH status at month 12 (high/norm-low
group). Only 16 patients (0.8%) had undergone para-
thyroidectomy before initiation of dialysis.
Treatments prescribed at month 0 to the 1983 patients are
given in Table 1: 980 patients (49.4%) were treated with
calcium-based phosphate binders, 687 patients (34.6%) were
treated with sevelamer, 224 patients (11.3%) were treated with
lanthanum carbonate, 131 patients (6.6%) were treated with
cinacalcet, and 256 (12.9%) patients underwent dialysis with a
high-calcium dialysate (1.75 mmol/L). Figure 2 shows treat-
ment doses prescribed at month 6. At month 6, a 1.75-mmol/L
calcium dialysate had been prescribed to 41 (11.4 %) of the
365 low-low patients, to 50 (18.3%) of the “high/normal-low”
patients, and to 131 (9.6%) of patients in the “others” groups.
At month 12, it was prescribed to 38 (10.4 %) of the 365
low-low patients, to 57 (20.2%) of the “high/normal-low”
patients, and to 134 (10%) of patients classiﬁed as “others”.3172 paƟents included
3030 paƟents with available iPTH
values at month 0
2164 hemodialysis paƟents at
month 12  
1983 paƟents with available iPTH
values at month 12
1322 hemodialysis paƟents at 
month 24
371 died
134 underwent transplantaƟon
276 were transferred to another 
center 
166 were lost to follow-up
250 died
132 underwent transplantaƟon
114 were transferred to another 
center 
165 were lost to follow-up
Figure 1 | Flow chart of patient enrollment and outcome from
month 0 (October 2010) to month 24 (October 2012). iPTH, intact
parathyroid hormone.
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From month 12 to month 24, 250 patients (12.6%) died—
105 (42%) from a CV cause and 145 (58%) from non-CV
causes.
Table 3 and Supplementary Tables S2 and S3 online show
the adjusted association between mortality and iPTH status.
Analyses for associations with all-cause mortality, CV
mortality, and non-CV mortality were successively conductedBlood hemoglobin, g/dl 11.28 (1.4) 1852
Intervention: phosphate binders, n (%)
Calcium-based binders 980 (49.4) 1983
Sevelamer hydrochloride 687 (34.6) 1983
Lanthanum carbonate 224 (11.3) 1983
Intervention: vitamin D, n (%)
Intravenous active vitamin D 19 (1.0) 1983
Oral active vitamin D 318 (16.0) 1983
Oral nonactive vitamin D 1112 (56.1) 1983
Intervention: cinacalcet, n (%) 131 (6.6) 1983
Intervention: calcium dialysate concentration, n (%)
1.25 mmol/L 37 (1.9) 1982
1.50 mmol/L 1496 (75.5) 1982
1.60 mmol/L 182 (9.2) 1982
1.65 mmol/L 11 (0.6) 1982
1.75 mmol/L 256 (12.9) 1982
iPTH, intact parathyroid hormone.
aContinuous variables are shown as mean and SD for normally distributed data and
the median and ﬁrst and third quartiles for non-normally distributed data. PTH status
is given according to the KDIGO recommendation of 2009 (deﬁned as “low” when
95% CI, 2 times the upper limit of normal values of measurement kit, “normal” when
2 to 9 times the upper limit of normal values, or “high” when >9 times the upper
limit of normal values).
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Table 2 | PTH status variability between month 0 (October
2010) and month 12 (October 2011) of 1983 incident patients
undergoing hemodialysisa
PTH status variability N %
Low-low 365 18.4
High/normal-low 282 14.2
High-low 16 0.8
Normal-low 266 13.4
Others 1336 67.4
High-high 59 3.0
High-norm 105 5.3
Norm-high 96 4.8
Norm-norm 838 42.3
Low-high 17 0.9
Low-norm 221 11.1
Total 1983 100
PTH, parathyroid hormone.
aPTH status is given according to the KDIGO recommendation of 2009 (deﬁned as
“low” when <2 times the upper limit of normal values of the used measurement kit,
“normal” when 2 to 9 times the upper limit of normal values, or “high” when >9
times the upper limit of normal values).
c l i n i ca l i nves t iga t i on E Merle et al.: Cardiovascular death and PTH decreaseusing month 0 PTH or month 12 PTH or PTH changes from
month 0 to month 12.
All-cause mortality. Neither low iPTH status at month
0 or month 12 nor PTH changes from month 0 to month 12
was independently associated with all-cause mortalityFigure 2 | Treatment dosage distribution of the 1983 incident patien
month 0 and month 12 included in the study. *Prescription of “nona
undergoing hemodialysis. Among them, 1020 patients (76.4%) received
only 7 patients (0.5%) received ergocalciferol. †Active vitamin D was rec
patients) were prescribed an i.v. vitamin D analogue.
668between month 12 and month 24 by Cox regression analysis
(see Table 3 for list of covariates). Age, low serum albumin,
and serum C-reactive protein (CRP) >10 mg/L were inde-
pendently associated with a higher all-cause mortality.
CV mortality. A low PTH status at month 0 was not
associated with increased CV mortality, and only a tendency
was observed for a low PTH status at month 12
(Supplementary Tables S2 and S3 online). Among patients
with a low PTH status at month 12, those in the “low-low”
PTH group (i.e., patients who had a low PTH status at both
month 0 and month 12) were not found to have an increased
risk of CV mortality (Table 3). Conversely, a “high/norm-
low” PTH variability status (patients with a high or normal
PTH status at month 0 and then a low PTH status at month
12; n ¼ 282) was independently associated with a 2 times
higher risk of cardiovascular death from month 12 to month
24 (hazard ratio [HR], 2.03; 95% conﬁdence interval [CI],
1.22–3.36; P ¼ 0.006), as shown in Table 3. In this subgroup,
the higher CV mortality risk was particularly true for the
norm-low subgroup (HR, 2.00; 95% CI, 1.14–3.5; P ¼ 0.016)
but was not shown for the small group of high-low patients
when the 9 possible PTH changes were separately investigated
(Supplementary Table S4 online).
Non-CV mortality. Neither the low PTH status at month
12 nor the 2 PTH variability status situations at monthts undergoing hemodialysis at month 6, with intact PTH values at
ctive” vitamin D was recorded in 1335 of the 1983 incident patients
cholecalciferol, 308 patients (23.1%) received 25-OH vitamin D, and
orded in 352 of the 1983 patients. Only 19 patients (1% of the 1983
Kidney International (2016) 89, 666–674
Table 3 | Association between mortality and PTH changes in 1983 incident patients undergoing hemodialysis with iPTH values
at month 0 and month 12a
Variable
All cause mortalityb Cardiovascular mortalityb Noncardiovascular mortalityb
HR 95% CI P value SHR 95% CI P value SHR 95% CI P value
PTH status variability
Low-low 1.33 0.96–1.85 0.089 1.09 0.62–1.92 0.756 1.43 0.93–2.18 0.104
High/normal-low 1.33 0.92–1.92 0.132 2.03 1.22–3.36 0.006c 0.87 0.50–1.49 0.600
Covariates
Age 1.04 1.03–1.05 <0.001 1.04 1.02–1.06 <0.001 1.04 1.02–1.06 <0.001
Female sex 0.92 0.68–1.27 0.626 0.95 0.61–1.49 0.838 0.93 0.59–1.47 0.770
Arterial hypertension 0.96 0.67–1.37 0.806 0.97 0.56–1.70 0.920 0.96 0.60–1.54 0.868
CV disease 1.37 0.97–1.94 0.077 2.11 1.22–3.66 0.008 0.97 0.61–1.53 0.887
Diabetes mellitus 1.16 0.87–1.54 0.322 0.96 0.61–1.50 0.845 1.37 0.93–2.01 0.110
Smoking 1.11 0.81–1.51 0.522 0.97 0.61–1.54 0.900 1.19 0.78–1.82 0.413
Serum albumin, g/L 0.91 0.89–0.94 <0.001 0.94 0.91–0.98 0.003 0.91 0.87–0.95 <0.001
Blood hemoglobin, g/dL – – – – – – – – –
Serum total calcium, mmol/L – – – – – – – – –
Serum phosphate, mmol/L – – – 1.92 1.29–2.85 0.001 0.64 0.41–1.01 0.057
Serum C-reactive protein, mg/L
5–10 1.29 0.86–1.93 0.226 1.08 0.58–2.03 0.802 1.44 0.86–2.41 0.170
10–20 1.86 1.24–2.78 0.003 1.50 0.80–2.83 0.205 2.08 1.21–3.56 0.008
> 20 2.71 1.87–3.94 <0.001 2.53 1.48–4.33 0.001 2.49 1.49–4.17 0.001
CI, conﬁdence interval; HR, hazard ratio; PTH, parathyroid hormone; SHR, subhazard ratio.
Dashes indicate covariates not remaining in the ﬁnal model considering their nonsigniﬁcant association at previous steps in the regression analysis.
aAll-cause, cardiovascular, and noncardiovascular mortality at month 12 to month 24 was evaluated for PTH status changes from month 0 to month 12 using adjusted Cox
analysis.
bAll models were estimated with Cox regression (all-cause mortality) or competing-risks regression models (cardiovascular and noncardiovascular mortality) and adjusted for
age, sex, presence of diabetes mellitus, hypertension and smoking, and prevalent cardiovascular events (cerebrovascular disease, ischemic heart disease, heart failure, and
peripheral artery disease). Tested covariates with backward selection were serum albumin, blood hemoglobin, serum calcium and phosphate, and C-reactive protein levels as
semiquantitative variables (reference group ¼ C-reactive protein#5 mg/L) at month 12. PTH changes were deﬁned according to the KDIGO PTH status at month 0 and month
12. A low-low classiﬁcation included patients with a low PTH level at month 0 and a low PTH level at month 12. A high/normal-low classiﬁcation included patients with a high
PTH or a normal PTH at month 0 and a low PTH at month 12. The reference group for PTH change analyses was “others,” which included patients with low-high or low-normal
or high-high or high-normal or normal-high or normal-normal changes, similarly deﬁned according to their month 0 and month 12 PTH status.
cSigniﬁcant association of “high-normal/low” PTH variability status and cardiovascular mortality.
E Merle et al.: Cardiovascular death and PTH decrease c l i n i ca l i nves t iga t ion12 (i.e., high/norm-low and low-low status) was found to be
associated with an increase in non-CV mortality. Only
low PTH at month 0 was associated with non-CV mortality
at month 0 to month 24 (HR, 1.41; 95% CI, 1.12–1.78;
P ¼ 0.004) (Supplementary Tables S2 and S3 online).
In summary, a decrease in serum iPTH in the ﬁrst year
of hemodialysis leading to a low PTH status was strongly
associated with an increased risk of CV death the year after,
independent of traditional CV risk factors or demographic,
inﬂammatory, nutritional, or mineral metabolism parame-
ters. Considering low PTH status recorded at month 0 or
month 12, no association with CV mortality was found; only
a low PTH at month 0 was associated with subsequent non-
CV mortality.
Predictive factors of PTH variability
To identify factors potentially responsible for iPTH changes
from month 0 to month 12, and particularly those that may
have contributed to the high-risk of CV death high/norm-low
status, we performed multivariate logistic regression analysis.
We aimed to identify factors at month 6 potentially associated
with the subsequent acquisition of low PTH status at month
12 in 282 patients, compared with those who maintained a
normal or high PTH status at month 12 (n ¼ 1098) (Table 4).
A lower serum albumin level at month 6 increased the risk of
a shift from “high/norm” to “low” status (odds ratio [OR],Kidney International (2016) 89, 666–6740.95 for þ1 g/L; 95% CI, 0.92–0.98; P ¼ 0.001). Concerning
the possible role of treatment modalities, a decrease in
iPTH level to a low status at month 12 was strongly associated
with the use of a high-calcium dialysate concentration
(1.75 mmol/L but not lesser calcium concentrations) (OR,
2.00; 95% CI, 1.35–3.01; P ¼ 0.001) and to a lesser extent
with an online hemodiaﬁltration mode of dialysis (OR, 1.48;
95% CI, 1.06–2.08; P ¼ 0.023) and with high doses of non-
active vitamin D (OR, 1.02 for þ1000 mg/6 months; 95% CI,
1.01–1.03 P ¼ 0.004), whereas the use of non–calcium-based
phosphate binders was associated with a reduced risk of
decreased PTH (OR, 0.91 for þ1 g/d; 95% CI, 0.85–0.98;
P ¼ 0.009 for sevelamer and OR, 0.97 for 100 mg/d;
95% CI, 0.95–0.99; P ¼ 0.033 for lanthanum carbonate).
There was only a trend for an association between PTH
decrease and use of calcium-based phosphate binders.
Predictive factors of CV mortality in patients with high/
norm-low PTH variability status
To determine avoidable factors responsible for the increased
CV mortality in the patients with acquired high/norm-low
PTH status at month 12 (n ¼ 282), we examined predictive
factors at month 12 for CV mortality at month 12 to month
24 in this subgroup using Cox regression analysis (Table 5). In
addition to age (HR, 1.05; 95% CI, 1.01–1.09; P ¼ 0.01) and
inﬂammation status as reﬂected by serum CRP levels (HR,669
Table 4 | Association between decreased iPTH between
month 0 and month 12 leading to a low month 12 PTH status
and demographics, biological, and treatment parameters at
month 6a
Variable
High/normal-lowb
OR 95% CI P value
Age, yr – – –
Female sex – – –
Cardiovascular disease – – –
Diabetes mellitus – – –
Body mass index, kg/m2 – – –
Kt/V – – –
Mo 0–mo 12 parathyroidectomy – – –
Cinacalcet, mg/d – – –
Calcium dose, g/d 1.12 0.99–1.28 0.077
Sevelamer, g/d 0.91 0.85–0.98 0.009
Lanthanum, þ100 mg/d 0.97 0.95–0.999 0.033
Active vitamin D, mg/wk – – –
Nonactive vitamin D, þ1000 mg/6 mo 1.02 1.01–1.03 0.004
Calcium dialysate concentration, mmol/Lc
1.60 or 1.65 1.20 0.74–1.93 0.459
1.75 2.00 1.35–2.95 0.001
Online hemodiaﬁltration 1.48 1.06–2.08 0.023
Serum albumin, g/L 0.95 0.92–0.98 0.001
Serum C-reactive protein, mg/Ld
5–10 – – –
10–20 – – –
>20 – – –
Serum phosphate, mmol/L – – –
Serum total calcium, mmol/L – – –
Serum 25-OH vitamin D3, ng/ml – – –
Blood hemoglobin, g/dl – – –
CI, conﬁdence interval; OR, odds ratio; PTH, parathyroid hormone.
Dashes indicate covariates not remaining in the ﬁnal model considering their
nonsigniﬁcant association at previous steps in the analysis.
aPatients with the “high/normal-low” PTH variability status (n ¼ 282 patients with a
high or normal PTH at month 0 and a low PTH at month 12) were compared with
patients with the “high/normal-high/normal” PTH variability status (n ¼ 1098 pa-
tients with a high or normal PTH at month 0 and a high or normal PTH at month 12).
bAdjusted ORs were obtained from the multivariate logistic regression model. Esti-
mates are reported for all independent predictors included in ﬁnal models.
cReference group ¼ 1.50 mmol/L.
dReference group ¼ <5 mg/L.
Table 5 | Association between cardiovascular mortality from
month 12 to month 24, and demographic, biological, and
treatment parameters recorded at month 12 in the high/
normal-low subgroup of patients (n [ 282 patients with a
high or normal PTH at month 0 and a low PTH at month 12)
Variable
Cardiovascular mortalitya
SHR 95% CI P value
Age, yr 1.05 1.01 - 1.09 0.010
Calcium dose, g/d – – –
Sevelamer, g/d – – –
Active vitamin D, mg/wk – – –
Native vitamin D, mg/6 mo – – –
Calcium dialysate concentration, mmol/Lb
1.60 or 1.65 0.90 0.16–5.009 0.900
1.75 5.44 2.52–11.75 <0.001
Online hemodiaﬁltration – – –
Serum albumin, g/L 0.91 0.85–0.98 0.013
Serum C-reactive protein, mg/Lc
5–10 0.50 0.09–2.75 0.429
10–20 5.35 1.57–18.20 0.007
>20 3.71 1.10–12.53 0.034
Serum phosphate, mmol/L – – –
Serum total calcium, mmol/L – – –
Blood hemoglobin, g/dl – – –
CI, conﬁdence interval; SHR, subhazard ratio.
Dashes indicate covariates not remaining in the ﬁnal model considering their
nonsigniﬁcant association at previous steps in the regression analysis
aAdjusted cardiovascular mortality was estimated with competing-risks regression.
Estimates are reported for all independent predictors included in ﬁnal models.
Cinacalcet and lanthanum were excluded from ﬁnal models because of lack of pa-
tients treated with these agents.
bReference group ¼ 1.50 mmol/L.
cReference group ¼ <5 mg/L.
c l i n i ca l i nves t iga t i on E Merle et al.: Cardiovascular death and PTH decrease5.35; 95% CI, 1.57–18.20; P ¼ 0.007 for CRP levels between
10 and 20 mg/L and HR, 3.71; 95% CI, 1.1–12.53; P ¼ 0.034
for CRP levels >20 mg/L), again, a high-calcium dialysate
concentration (1.75 mmol/L but not lesser concentrations)
was strongly associated with increased CV mortality (HR,
5.44; 95% CI, 2.52–11.75; P < 0.001 when compared with
dialysate calcium concentration #1.50 mmol/L). No other
treatment prescription was found to be associated with
subsequent CV mortality in this subgroup of patients. Note
that the same analysis in the PTH low-low subgroup of
patients (n ¼ 365) did not ﬁnd a high-calcium dialysate
(1.75 mmol/L) to be associated with CV mortality at month
12 to month 24 (HR, 0.51; 95% CI, 0.67–3.96; P ¼ 0.52)
(data not shown).
DISCUSSION
This national prospective observational study focused on PTH
status and its changes over time as a potential predictor of
mortality in patients with CKD stage 5 after the initiation of670maintenance hemodialysis therapy. PTH status was deﬁned
according to the 2009 Kidney Disease: Improving Global Out-
comes (KDIGO) guideline at dialysis time zero or 12 months
later, or both. We found that a decrease in serum iPTH from
high or normal to low levels (high/norm-low PTH status)
during the ﬁrst year of hemodialysis, but not other low PTH
status situations, was an independent and strong risk factor
for CV death in the following year. The association of high/
norm-low PTH status with a 2-fold increase in CV mortality
risk had a predictive weight similar to that of a prevalent CV
disease, hyperphosphatemia, or inﬂammation status. We
further established that the main potential contributor to the
observed decrease in serum iPTH associated with the risk of
high CV death was the use of a high-calcium dialysate con-
centration (1.75 mmol/L). Finally, we found that in patients
who acquired the high/norm-low PTH status during the
ﬁrst year of dialysis, the initiation or continued use of a high-
calcium dialysate concentration was associated with a 5-fold
increase in CV death risk during the second year of dialysis.
Our results are in accordance with previous reports of an
association between low serum PTH levels and all-cause
mortality in prevalent patients undergoing hemodialy-
sis.11,13,19–22 Only Naves-Diaz et al.19 reported an increase in
CV mortality risk in patients with low PTH levels. However,
all these studies included prevalent patients with large
heterogeneity in dialysis vintage as the main confoundingKidney International (2016) 89, 666–674
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undergoing hemodialysis, and this strengthens its ﬁndings.
More importantly, investigating the relationship between
longitudinal changes in PTH status and mortality allowed us
to show that after 1 year, only patients who had decreased
iPTH levels from high or normal values to low values were at
higher risk of short-term CV death. In contrast, those who
already were at a low PTH status at month 0 and remained so
at month 12 had no increase in CV death risk. The only
previous study that investigated the effect of changes in iPTH
levels on mortality risk in incident patients undergoing
dialysis is that by Drechsler et al.23 They showed that a
decrease in iPTH over 3 months was associated with a higher
risk of all-cause mortality in those with decreased body mass
index. However, in that study, the changes in iPTH were likely
a surrogate marker of changes in body mass index, with a
probable link to all-cause mortality through protein energy
wasting or malnutrition, or both. In our cohort, a PTH
decrease was found to be a risk factor for CV death inde-
pendent of protein energy wasting (low albumin level) and
inﬂammation (high CRP level) (Table 3). It has been clearly
shown that the CV state, and in particular the presence of
arterial calciﬁcation, in patients undergoing maintenance
hemodialysis is associated with increased CV risk5,16,17,24 and
mortality.24-26 It has been reported repeatedly that an exces-
sive decrease in iPTH may favor the development of low bone
turnover disease27 and arterial calciﬁcation. Thus, the clinical
concern of an association of low PTH status and CV calciﬁ-
cation is supported by our results, even though the hypothesis
that low PTH might have increased CV morbidity through
accelerated calciﬁcation over such a short time remains
hypothetical and calls for future investigation. Nonetheless,
the reason that a progressive decrease in iPTH, but not
sustained low iPTH levels, is associated with CV mortality
remains a matter of conjecture.
A decrease in PTH levels had been previously associated
with an increase in dialysate calcium concentration and even
proposed as an efﬁcient strategy for containing secondary
hyperparathyroidism.28 Accordingly, we identiﬁed the use of a
high-calcium dialysate concentration (1.75 mmol/L) at
month 6 as the strongest contributor to a PTH decrease, but
we added that its maintenance (or initiation) at month 12 in
patients who had acquired the high/norm-low PTH status
was associated with a > 5-fold higher short-term risk of CV
death. Up to now, only the Dialysis Outcomes and Practice
Patterns Study (DOPPS) investigators in 2005 and a recent
prospective study have linked a high-calcium dialysate to an
increase in all-cause mortality but not to CV death or CV
morbidity.15,29 Considering the mechanisms underlying the
association between a high-calcium dialysate and CV mor-
tality in patients with a high/norm-low status in our cohort,
we hypothesize, as previously formulated by London,17 that
deposition in vascular tissue may be facilitated by a high
intradialytic calcium load, in conjunction with low PTH
status and low bone turnover, favoring calcium accumulation
in cardiovascular tissues instead of bone and the occurrenceKidney International (2016) 89, 666–674of CV disease. Nonetheless, this hypothesis is challenged by
the contrasting observation that high-calcium dialysate use
was not found to be associated with a higher risk of CV death
in patients with a low PTH throughout (the low-low
patients), who likely had a similar low bone turnover status.
This suggests that alternative or complementary mechanisms
involved in the effects of high-calcium dialysates remain to be
identiﬁed. A high level of serum ﬁbroblast growth factor
23 (FGF-23) is a good candidate for such a role regarding its
close association with CV morbidity and mortality in patients
undergoing dialysis and considering that patients undergoing
dialysis with high-calcium dialysates may have even higher
levels of serum FGF-23.30 Unfortunately, FGF-23 measure-
ments were not available in our study. Moreover, the possi-
bility of a high FGF-23–driven poor CV prognosis in the
high/norm-low PTH patients treated with a high-calcium
dialysate would appear to be in contradiction to the obser-
vation that decreasing PTH levels are associated with a fall in
serum FGF-23 in patients undergoing dialysis.31-34
The use of non–calcium-based phosphate binders at
month 6 was shown to be protective against the development
of low PTH status at month 12. A recent meta-analysis by
Jamal et al.35 found a survival advantage with the use of
calcium-free binders with regard to all-cause mortality,
compared with the use of calcium-based phosphate binders;
however, information on CV mortality was not provided. Our
ﬁndings are compatible with the hypothesis that calcium-free
phosphate binders indirectly exert CV protection by avoiding
a progressive decrease in serum PTH or by avoiding calcium
load associated with calcium-based phosphate binders, or
both. However, the absence of a clear PTH-reducing effect of
calcium salts (only a trend was found) weakens this
hypothesis and suggests other mechanisms. We did not ﬁnd
an association between cinacalcet use and decreases in iPTH.
One possible explanation is that patients treated with cina-
calcet underwent particularly close iPTH monitoring. The
fact that native vitamin D can lower iPTH and, vice versa, that
vitamin D deﬁciency increases iPTH is well established.15,36
Accordingly, in our study, the prescription of high non-
active vitamin D doses at month 6 was weakly associated with
high/norm-low PTH status but was not a factor at month
12 of increased CV mortality risk between month 12 and
month 24. Finally, in accordance with the results by Drechsler
et al.37 we found that low serum albumin levels were also
associated with a decrease in serum iPTH.
A major strength of the present study is that it included
a large cohort of incident patients undergoing dialysis,
allowing longitudinal synchronization of data from the
beginning of dialysis treatment. Supporting our ﬁndings are
the prospective collection of data over 2 years with <10% loss
to follow-up; the representativeness of our cohort of the
French incident hemodialysis patient population; the multi-
center nature of our study with inclusion of 25% of the
incident patients undergoing hemodialysis in France in 2010
with similar characteristics38; CV mortality as a major
end point of our analyses, which were adjusted for major671
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variability based on PTH categorization by KDIGO recom-
mendations, with international relevance of the results.
There are also limitations in our study. Centers enrolled
may be more interested in iPTH monitoring and compliant
with KDIGO recommendations than those that did not join
the study group. The patient cohort as a whole reached the
stage of dialysis with a low prevalence of KDIGO-deﬁned high
PTH status (10.3%). Thus, these patients could be seen as
having well-controlled or even overtreated secondary hyper-
parathyroidism. This pattern may not be reﬂective of incident
patient cohorts in other countries. Some clinical and
biochemical data were not available, such as indicators of
residual renal function and serum magnesium levels. Serum
biochemistry evaluations were performed locally, with some
heterogeneity of calibration and protocols. Treatment
recording was based on notiﬁcation every 6 months in the
database, which is consistent with momentary prescription
but may not precisely reﬂect dosage changes during each
period. Some treatments were not recorded, such as magne-
sium or bicarbonate/acetate dialysate composition. We were
not able to weigh general morbidity burden in our models
because data required for Charlson, Davies, or Khan scores
were not available. Our study was observational in nature,
and therefore its results are only hypothesis generating.
Finally, because it was conducted exclusively in incident
patients undergoing dialysis, it remains to determine whether
its ﬁndings could be generalized to any period after the start
of dialysis.
In conclusion, this study extends previous observations in
several ways. First, it conﬁrms recent reports by several groups
of a signiﬁcant proportion of patients undergoing mainte-
nance hemodialysis with low PTH status. Second, it adds to
established knowledge that the induction of a low PTH status
is an independent strong risk factor for CV death. Third, it
highlights the fact that interventions such as the use of very
high-calcium dialysate concentrations (1.75 mmol/L) should
be considered with caution because they may induce a dele-
terious low PTH status with an increased risk of CV death.
Our observation also appears to be in support of the KDIGO
guideline, which suggests avoiding high-calcium dialysate
concentrations to prevent soft tissue calciﬁcations.
METHODS
Study design and population
The French Phosphate and Calcium Observatory is a prospective
multicenter observational study established in 2005. Our study is
part of the “Photo-Graph 3” study that started in October 2010 and
lasted until April 2014, whose principal aim was to deﬁne the pro-
portion of patients with chronic kidney disease who reached KDIGO
recommended treatment targets. A total of 250 to 300 nephrologists
from public, private, or not-for-proﬁt centers in France were asked
to participate. They were chosen by cluster sampling to reach the
calculated necessary sample size of 230 nephrologists. Data were
collected every 6 months using an electronic case-report system
(Photo-Graph software) developed by Genzyme (a Sanoﬁ company,
Paris, France). Data collection was performed and the anonymity of672patients was maintained at both the regional and national levels in
accordance with the ethics committee guidelines. Investigators were
not aware of the present study concerning PTH status and mortality
until October 2012. No pre-established treatment protocols were
suggested except indirectly those included in current international
guidelines when they exist. Consequently, treatment prescriptions
such as calcium dialysate concentration were likely subjective or
related to the nephrologists’ personal experience, or both. The study
included the subpopulation of the Photo-Graph 3 cohort deﬁned as
all adult patients (aged$ 18 years) who started chronic hemodialysis
treatment within 6 months of October 2010, deﬁned as month 0.
Patient data were prospectively recorded at 6-month intervals for 2
years, that is, until October 2012, deﬁned as month 24. Except for
the association between PTH status at month 0 and subsequent
mortality, patients who died during the ﬁrst year of follow-up be-
tween October 2010 and October 2011 (month 12) were excluded
from the analysis, because the study reported on the association
between PTH status at month 12 and mortality during the second
year of follow-up. Patients who received a kidney graft or were lost to
follow-up were included in the analyses, with data recorded until
renal transplantation or the last available data. All laboratory
evaluations were performed locally.
Expression of serum iPTH data
For data analyses, iPTH was analyzed as a semiquantitative variable
with ranges deﬁned as low (< 2 times the upper limit of normal
values for the measurement kit used), normal (2–9 times the upper
limit of normal values), or high levels (> 9 times the upper limit of
normal values) according to the KDIGO guideline of 2009.18 Patient
groups were established according to their iPTH status (low, normal,
or high) at month 0 and month 12. We ﬁrst studied the impact of
iPTH status at month 0 and month 12 and then designed 3 groups of
patients who were categorized according to variations of serum iPTH
levels between month 0 and month 12: low-low for patients with a
low PTH status at both month 0 and month 12; high/norm-low for
patients with a normal or high PTH status at month 0, decreasing to
a low status at month 12; and others for patients with other PTH
status changes between month 0 and month 12.
Study outcomes
The primary end points were all-cause mortality, CV mortality, and
non-CV mortality from month 12 to month 24 according to PTH
status at month 12 or to PTH status change between month 0 and
month 12 and from month 0 to month 24 according to PTH status
at month 0. Secondary outcomes were factors predictive of PTH
status variability between month 0 and month 12.
Statistical analyses
Data were analyzed with basic descriptive statistics. Associations with
all-cause mortality are expressed as HRs and were estimated with
Cox proportional hazards regression modeling. When cardiovascular
death (respiratory noncardiovascular death) was studied,
noncardiovascular death (respiratory cardiovascular death) was
coded as a competitive risk, competing-risks regression models were
used (method of Fine and Gray39, “stcrreg” Stata command), and
associations with mortality are expressed as subhazard ratios. The
potential confounders age, sex, presence of diabetes mellitus,
hypertension, smoking, and prevalent cardiovascular events (cere-
brovascular disease, ischemic heart disease, heart failure, and
peripheral artery disease) at month 12 were maintained as
adjustment factors in ﬁnal models whatever their signiﬁcance. TheKidney International (2016) 89, 666–674
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and phosphate levels (analyzed as continuous variables), and CRP
(analyzed as a semiquantitative variable: reference value #5 mg/L, 5
to #10 mg/L, 10 to #20 mg/L, and >20 mg/L), were selected using
backward selection (selection of covariates by stepwise regression
with a threshold at 0.2, followed by 1 by 1 removal of covariates with
comparison between 2 adjacent models using Akaike’s information
criterion and Bayesian information criterion).
The biochemical parameters were evaluated at the time of iPTH
measurements (at month 0 or month 12) together with analyses of
associations of PTH status and mortality between month 12 and
month 24 and with analyses (at month 12) of the impact of PTH
status changes between month 0 and month 12 on mortality between
month 12 and month 24.
Predictive factors of PTH status variability between month 0 and
month 12 were analyzed by multivariate logistic regression,
expressing odds ratios for each factor. Demographic parameters and
medical history were recorded at month 0, and biochemical and
therapeutic parameters were recorded at month 6. Parameters
assessed at month 0 were age, sex, cardiovascular disease, diabetes
mellitus, previous parathyroidectomy, and body mass index. Pa-
rameters assessed at month 6 were Kt/V; serum levels of albumin,
phosphate, calcium, and 25-OH vitamin D; blood hemoglobin level;
and prescribed oral doses of cinacalcet, sevelamer hydrochloride,
lanthanum carbonate, calcium-based phosphate binders, and active
or nonactive vitamin D sterols (native vitamin D and 25-OH vitamin
D). These parameters were analyzed as quantitative variables. Values
of nonactive vitamin D intake were expressed in micrograms per 6
months using the conventional conversion of 1 mg cholecalciferol ¼
40 IU.40 Serum CRP and dialysate calcium concentrations (reference
value #1.50 mmol/L, 1.60 or 1.65 mmol/L, 1.75 mmol/L) at month
6 were analyzed as semiquantitative variables. In case of missing data,
the patient was not included in analyses needing such data.
We calculated 95% conﬁdence intervals (CIs) for all estimates.
Statistical analyses were performed with Stata 13 software (StataCorp
LP, College Station, TX).DISCLOSURE
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support.SUPPLEMENTARY MATERIAL
Supplementary Table S1. Demographics, clinical characteristics, and
treatment at study entry (month 0) of the 3030 incident hemodialysis
patients included in the cohort with available serum intact
parathyroid hormone (PTH) at month 0. Continuous variables are
shown as the mean and SD for normally distributed data and the
median and 1st and 3rd quartiles for nonnormally distributed data.Kidney International (2016) 89, 666–674PTH status is given according to the KDIGO recommendation of 2009
(deﬁned as “low”when<2x the upper limit of normal values of the used
measurement kit, “normal” when 2–9x the upper limit of normal values,
or “high” when >9x the upper limit of normal values) at month 0.
Supplementary Table S2. Association between mortality and month
0 parathyroid hormone (PTH) status in 3030 incident hemodialysis
patients with available intact PTH at month 0. All-cause, cardiovas-
cular, and noncardiovascular mortality at month 0 to month 24 were
evaluated for PTH status assessed at month 0 using adjusted Cox
analysis.
Supplementary Table S3. Association between mortality and month
12 parathyroid hormone (PTH) status in 1983 incident hemodialysis
patients with intact PTH values at month 0 and month 12. All-cause,
cardiovascular, and noncardiovascular mortality at month 12 to
month 24 were evaluated for PTH status assessed at month 12 using
adjusted Cox analysis.
Supplementary Table S4. Association between month 12 to month
24 cardiovascular mortality and parathyroid hormone (PTH) changes
in 1983 incident hemodialysis patients with intact PTH values at
month 0 and month 12 according to 9 groups of PTH status
variability, using adjusted Cox analysis.
Supplementary material is linked to the online version of the paper at
www.kidney-international.org.
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